Kainos Medicine, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kainos Medicine, Inc.
As South Korean companies jump into the development of vaccines and drugs for the coronavirus, they also call for stronger government support and increased collaboration between the state and private sectors.
Syntekabio is at the forefront of artificial intelligence-driven new drug development in South Korea. Its CEO Tyson Kim talks to Scrip how the genome big data and AI platform company is helping the pharma industry to develop new drugs more efficiently and rapidly.
Kainos Medicine's HIV drug candidate KM-023 is set to move directly into a Phase III program in China through local licensee Jiangsu Aidea, benefiting from the country's fast-track review system and accelerating the development of the drug, which Kainos sees as bringing multiple possible benefits over existing therapies.
Asterias obtains IP estate related to ischemic stroke from University of California. Plus Apeiron, Qualigen, Biovaxys and AbbVie turn to academic partners for early-stage cancer assets.